A patient with endometriosis is being treated with the gonadotropin-releasing hormone (GnRH) agonist leuprolide [Lupron Depot]. A nurse is teaching the patient about the drug. Which state-ment by the patient indicates understanding of the teaching?
a. "I can continue to take the medication if I get pregnant."
b. "I can expect the medication to cure my symptoms."
c. "I may have menopausal-like symptoms when taking this medication."
d. "I will need to take the medication for several years."
C
Because the GnRH agonists deprive the ovary of the stimulation to produce estrogen, women may experience symptoms associated with menopause, including hot flashes, vaginal dryness, decreased libido, mood changes, and headache. GnRH agonists are teratogenic and should not be used during pregnancy. The medication does not produce a cure; symptoms return in up to 50% of women after discontinuation of the drug. GnRH agonists should be discontinued after 6 months of treatment because of the risk of osteoporosis.
You might also like to view...
An adult patient who is currently undergoing rhinoplasty has developed the characteristic signs and symptoms of malignant hyperthermia. The operating room nurse should anticipate what intervention?
A) Hemodialysis B) Tracheal intubation C) IV administration of naloxone (Narcan) D) IV administration of dantrolene sodium (Dantrium)
A nurse who is caring for a client with Paget's disease should plan which nursing intervention?
1. Do all client care activities at one time. 2. Encourage the client to stay out of bed most of the day. 3. Keep the client on bed rest. 4. Teach the client how to apply a back brace.
A 26-year-old pregnant woman, gravida 2, para 1-0-0-1 is 28 weeks pregnant when she experiences bright red, painless vaginal bleeding. On her arrival at the hospital, what would be an expected diagnostic procedure?
a. Amniocentesis for fetal lung maturity b. Ultrasound for placental location c. Contraction stress test (CST) d. Internal fetal monitoring
The greatest concern about using trovafloxacin and alatrofloxacin is the development of:
1. hepatotoxicity. 2. weight loss. 3. visual disturbances. 4. anemia.